Posts tagged ImPACT
Roth starts Heat Biologics at buy

Roth Capital Partners has initiated coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $2.75 price target. The stock closed at 60 cents on Friday.

“Heat Biologics possesses a portfolio of unique, differentiated vaccines that, in our opinion, could bring a much needed boost to the cancer vaccine space, which has been plagued by recent failures,” writes analyst Joseph Pantginis.

Read More